CN102448488B - 支原体感染症用疫苗 - Google Patents
支原体感染症用疫苗 Download PDFInfo
- Publication number
- CN102448488B CN102448488B CN201080023429.2A CN201080023429A CN102448488B CN 102448488 B CN102448488 B CN 102448488B CN 201080023429 A CN201080023429 A CN 201080023429A CN 102448488 B CN102448488 B CN 102448488B
- Authority
- CN
- China
- Prior art keywords
- mycoplasma
- particles
- lipidantigen
- specificity
- liposome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
Claims (19)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009135592 | 2009-06-04 | ||
JP2009-135592 | 2009-06-04 | ||
JP2009271633 | 2009-11-30 | ||
JP2009-271633 | 2009-11-30 | ||
PCT/JP2010/003732 WO2010140377A1 (ja) | 2009-06-04 | 2010-06-04 | マイコプラズマ感染症用ワクチン |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102448488A CN102448488A (zh) | 2012-05-09 |
CN102448488B true CN102448488B (zh) | 2014-10-15 |
Family
ID=43297520
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201080023429.2A Active CN102448488B (zh) | 2009-06-04 | 2010-06-04 | 支原体感染症用疫苗 |
Country Status (10)
Country | Link |
---|---|
US (2) | US9539209B2 (zh) |
EP (1) | EP2438926B1 (zh) |
JP (2) | JP5968622B2 (zh) |
KR (3) | KR101795524B1 (zh) |
CN (1) | CN102448488B (zh) |
AU (1) | AU2010255182B2 (zh) |
CA (1) | CA2764424C (zh) |
HK (1) | HK1170421A1 (zh) |
TW (1) | TWI583403B (zh) |
WO (1) | WO2010140377A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102448488B (zh) * | 2009-06-04 | 2014-10-15 | 独立行政法人产业技术综合研究所 | 支原体感染症用疫苗 |
US11529312B2 (en) * | 2016-04-07 | 2022-12-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Francisella lipids as broad anti-inflammatory therapeutics and associated methods of use |
CN108101969A (zh) * | 2017-11-13 | 2018-06-01 | 南京大爻网络科技有限公司 | 一种与猪支原体肺炎相关的抗原及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1263470A (zh) * | 1997-05-19 | 2000-08-16 | 住友制药株式会社 | 免疫增强组合物 |
WO2008014979A2 (en) * | 2006-07-31 | 2008-02-07 | Curevac Gmbh | NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT |
JP2009007279A (ja) * | 2007-06-27 | 2009-01-15 | M Bio Tech Kk | マイコプラズマニューモニエ特異抗原糖脂質の合成方法 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH569258A5 (zh) | 1973-12-05 | 1975-11-14 | Zeiss Carl Fa | |
JPS6250665A (ja) * | 1985-08-30 | 1987-03-05 | Denka Seiken Co Ltd | 肺炎マイコプラズマ抗体価の測定法 |
JP2828391B2 (ja) | 1993-10-29 | 1998-11-25 | 東燃株式会社 | オリゴ糖を表面に有するリポソーム |
JP3717962B2 (ja) * | 1994-03-18 | 2005-11-16 | 有限会社エム ライフサイエンス研究所 | グリセロ糖脂質化合物の製造法 |
JP3735388B2 (ja) * | 1994-06-03 | 2006-01-18 | エム バイオ テック株式会社 | 新規グリセロ糖リン脂質とその抗体及びマイコプラズマの検出法 |
EP1071452A1 (en) * | 1998-04-13 | 2001-01-31 | Brigham Women's Hospital, Inc. | Vaccine compositions comprising cd-1 antigens and t-cell stimulating compound and methods of use thereof |
GB9813100D0 (en) | 1998-06-18 | 1998-08-19 | Secr Defence | Method of forming liposomes |
ID29082A (id) | 1998-09-22 | 2001-07-26 | Molecular Express Inc | Komposisi liposom imunogenik |
GB9822619D0 (en) * | 1998-10-19 | 1998-12-09 | Porter William L | Immune response stimulation |
JP3589912B2 (ja) | 1999-09-03 | 2004-11-17 | 泰久 福井 | ホスファチジルイノシトール−3,4−二リン酸を認識するモノクローナル抗体 |
IL149471A0 (en) | 1999-11-08 | 2002-11-10 | Biomune | Vaccines for mycoplasma bovis and methods for immunizing bovine amimals |
JP3594544B2 (ja) | 2000-09-27 | 2004-12-02 | 三洋電機株式会社 | 冷蔵庫 |
MXPA03003401A (es) | 2000-10-16 | 2004-06-30 | Neopharm Inc | Formulacion liposomica de mitoxantrona. |
MY129765A (en) | 2000-12-19 | 2007-04-30 | Wyeth Corp | Improved mycoplasma hyopneumoniae bacterin vaccine |
JP3943845B2 (ja) | 2001-02-15 | 2007-07-11 | 芳枝 米谷 | リポソームベクター |
WO2002098465A2 (en) | 2001-06-07 | 2002-12-12 | Celator Technologies, Inc. | Cell penetrating therapeutic agents |
US20030147914A1 (en) | 2001-07-02 | 2003-08-07 | Pfizer Inc. | Mycoplasma bovis vaccine and methods of reducing pneumonia in animals |
CA2452666A1 (en) | 2001-07-02 | 2003-01-16 | Pfizer Products Inc. | Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle |
ATE412426T2 (de) | 2001-07-02 | 2008-11-15 | Pfizer Prod Inc | Vakzination in einer dosis mit i mycoplasma hyopneumoniae /i |
JP3415131B1 (ja) | 2002-06-03 | 2003-06-09 | メビオファーム株式会社 | リポソーム製剤 |
JP2004043332A (ja) * | 2002-07-09 | 2004-02-12 | Nof Corp | 経口用リポソーム製剤 |
AU2002951692A0 (en) | 2002-09-23 | 2002-10-17 | Vital Biotech (Hong Kong) Limited | Improvements in or relating to vaccines |
JP4712341B2 (ja) | 2003-10-20 | 2011-06-29 | 日油株式会社 | リン脂質膜製剤 |
CA2587103A1 (en) * | 2004-11-08 | 2006-05-18 | Neopharm, Inc. | Synthesis of cardiolipin analogues and uses thereof |
JP2006311824A (ja) | 2005-05-09 | 2006-11-16 | National Agriculture & Food Research Organization | 豚マイコプラズマ肺炎ワクチン |
US20070009545A1 (en) | 2005-07-07 | 2007-01-11 | Joachim Frey | Mycoplasma subunit vaccine |
WO2007023583A1 (ja) | 2005-08-22 | 2007-03-01 | National University Corporation Nagoya University | 糖脂質誘導体合成中間体及びその製造方法、並びに糖脂質誘導体及びその製造方法 |
KR100750327B1 (ko) | 2005-08-23 | 2007-08-17 | 가부시키가이샤 엔.티.티.도코모 | 전송 속도 제어 방법, 이동국, 무선 기지국 및 무선네트워크 제어국 |
JP2007145362A (ja) | 2005-11-28 | 2007-06-14 | Toyobo Co Ltd | 酸素透過性を制御された袋 |
JP2007145361A (ja) | 2005-11-28 | 2007-06-14 | Toray Ind Inc | 納豆容器 |
JP2007238470A (ja) | 2006-03-06 | 2007-09-20 | Univ Nagoya | 糖脂質誘導体及びその製造方法、ウイルス感染阻害剤、トイレタリー用品、並びにウイルス感染予防装置 |
JP4386290B2 (ja) | 2006-04-20 | 2009-12-16 | 日本電信電話株式会社 | 省電力無線lanマルチキャスト通信品質制御方法およびその無線基地局装置 |
JPWO2007132790A1 (ja) * | 2006-05-12 | 2009-09-24 | 国立大学法人 北海道大学 | 細菌菌体成分を含む脂質膜を有するリポソーム |
WO2007145361A1 (ja) | 2006-06-14 | 2007-12-21 | M Bio Technology Inc. | マススペクトロメーターを用いた脂質抗原検出法 |
EP2048239B1 (en) | 2006-06-14 | 2015-08-12 | M Bio Technology Inc. | Glyceroglycolipid antigen of mycoplasma pneumoniae |
JP2008037831A (ja) | 2006-08-09 | 2008-02-21 | Nof Corp | T細胞活性化剤 |
JPWO2009060710A1 (ja) | 2007-11-06 | 2011-03-24 | 国立大学法人徳島大学 | リポソームに抗体結合能を付与するペプチド、および当該ペプチドで修飾されたリポソーム |
CN102448488B (zh) * | 2009-06-04 | 2014-10-15 | 独立行政法人产业技术综合研究所 | 支原体感染症用疫苗 |
-
2010
- 2010-06-04 CN CN201080023429.2A patent/CN102448488B/zh active Active
- 2010-06-04 KR KR1020117027253A patent/KR101795524B1/ko active IP Right Grant
- 2010-06-04 KR KR1020177016162A patent/KR20170077255A/ko not_active Application Discontinuation
- 2010-06-04 TW TW099118115A patent/TWI583403B/zh active
- 2010-06-04 EP EP10783165.3A patent/EP2438926B1/en active Active
- 2010-06-04 KR KR1020187017843A patent/KR102185682B1/ko active IP Right Grant
- 2010-06-04 US US13/376,009 patent/US9539209B2/en active Active
- 2010-06-04 CA CA2764424A patent/CA2764424C/en active Active
- 2010-06-04 WO PCT/JP2010/003732 patent/WO2010140377A1/ja active Application Filing
- 2010-06-04 JP JP2011518281A patent/JP5968622B2/ja active Active
- 2010-06-04 AU AU2010255182A patent/AU2010255182B2/en active Active
-
2012
- 2012-11-07 HK HK12111224.1A patent/HK1170421A1/zh unknown
-
2016
- 2016-05-06 JP JP2016093076A patent/JP6465313B2/ja active Active
- 2016-12-13 US US15/377,291 patent/US10232026B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1263470A (zh) * | 1997-05-19 | 2000-08-16 | 住友制药株式会社 | 免疫增强组合物 |
WO2008014979A2 (en) * | 2006-07-31 | 2008-02-07 | Curevac Gmbh | NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT |
JP2009007279A (ja) * | 2007-06-27 | 2009-01-15 | M Bio Tech Kk | マイコプラズマニューモニエ特異抗原糖脂質の合成方法 |
Non-Patent Citations (8)
Title |
---|
Barbour EK et.al..Preliminary data on efficacy of Mycoplasma gallisepticum vaccines containing different adjuvants in laying hens.《Vet Immunol Immunopathol》.1990,第26卷(第2期), |
Christopher C.Dascher et.al..Immunization with a mycobacterial lipid vaccine improves pulmonary pathology in the guinea pig model of tuberculosis.《International Immunology》.2003,第15卷(第8期), |
Immunization with a mycobacterial lipid vaccine improves pulmonary pathology in the guinea pig model of tuberculosis;Christopher C.Dascher et.al.;《International Immunology》;20031231;第15卷(第8期);摘要部分,第918页右栏第28行至第919页右栏第3行,第924页右栏第7-10行,图2 * |
Ken B.Waites et.al..Mycoplasma pneumoniae and Its Role as a Human Pathogen.《CLINICAL MICROBIOLOGY REVIEWS》.2004,第17卷(第4期), |
Molecular Biology and Pathogenicity of Mycoplasmas;SHUMEL RAZIN et.al.;《MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS》;19981231;第62卷(第4期);1094-1156页 * |
Mycoplasma pneumoniae and Its Role as a Human Pathogen;Ken B.Waites et.al.;《CLINICAL MICROBIOLOGY REVIEWS》;20041031;第17卷(第4期);697-728页 * |
Preliminary data on efficacy of Mycoplasma gallisepticum vaccines containing different adjuvants in laying hens;Barbour EK et.al.;《Vet Immunol Immunopathol》;19901031;第26卷(第2期);115-123页 * |
SHUMEL RAZIN et.al..Molecular Biology and Pathogenicity of Mycoplasmas.《MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS》.1998,第62卷(第4期), |
Also Published As
Publication number | Publication date |
---|---|
CN102448488A (zh) | 2012-05-09 |
US20120135067A1 (en) | 2012-05-31 |
TW201105365A (en) | 2011-02-16 |
KR20120028880A (ko) | 2012-03-23 |
JPWO2010140377A1 (ja) | 2012-11-15 |
EP2438926A1 (en) | 2012-04-11 |
JP2016172754A (ja) | 2016-09-29 |
KR20180074804A (ko) | 2018-07-03 |
EP2438926B1 (en) | 2016-03-23 |
KR101795524B1 (ko) | 2017-11-08 |
EP2438926A4 (en) | 2013-07-24 |
AU2010255182B2 (en) | 2016-03-10 |
JP5968622B2 (ja) | 2016-08-10 |
JP6465313B2 (ja) | 2019-02-06 |
TWI583403B (zh) | 2017-05-21 |
HK1170421A1 (zh) | 2013-03-01 |
US10232026B2 (en) | 2019-03-19 |
AU2010255182A1 (en) | 2011-12-15 |
US20170165343A1 (en) | 2017-06-15 |
KR102185682B1 (ko) | 2020-12-11 |
US9539209B2 (en) | 2017-01-10 |
CA2764424A1 (en) | 2010-12-09 |
KR20170077255A (ko) | 2017-07-05 |
CA2764424C (en) | 2019-12-31 |
WO2010140377A1 (ja) | 2010-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lagousi et al. | Novel protein-based pneumococcal vaccines: assessing the use of distinct protein fragments instead of full-length proteins as vaccine antigens | |
US7491517B2 (en) | Method of producing meningococcal meningitis vaccine for Neisseria meningitidis serotypes A,C,Y, and W-135 | |
US11771751B2 (en) | Streptococcal GlcNAc-lacking glycopolypeptides, cell wall carbohydrates, streptococcus vaccines, and methods for making and using them | |
Emmadi et al. | A Streptococcus pneumoniae type 2 oligosaccharide glycoconjugate elicits opsonic antibodies and is protective in an animal model of invasive pneumococcal disease | |
Hu et al. | Exploiting bacterial outer membrane vesicles as a cross-protective vaccine candidate against avian pathogenic Escherichia coli (APEC) | |
Deng et al. | A peptide-free, liposome-based oligosaccharide vaccine, adjuvanted with a natural killer T cell antigen, generates robust antibody responses in vivo | |
CN102448488B (zh) | 支原体感染症用疫苗 | |
Palmieri et al. | Stability of outer membrane vesicles-based vaccines, identifying the most appropriate methods to detect changes in vaccine potency | |
CN102648003B (zh) | 选择性裂解的全细胞疫苗 | |
JPH01500119A (ja) | Gm2に対する抗体の産生を賦活又は増強させるためのワクチン | |
Tada et al. | Polymeric caffeic acid acts as a nasal vaccine formulation against streptococcus pneumoniae infections in mice | |
Khan et al. | Safety and prophylactic efficacy of liposome-based vaccine against the drug-resistant Acinetobacter baumannii in Mice | |
Khan et al. | Glycosphingolipids (GSLs) from Sphingomonas paucimobilis Increase the efficacy of liposome-based nanovaccine against Acinetobacter baumannii-associated pneumonia in immunocompetent and immunocompromised mice | |
Salman et al. | First characterization of immunogenic conjugates of Vi negative Salmonella Typhi O-specific polysaccharides with rEPA protein for vaccine development | |
RU2371196C1 (ru) | Способ определения предельно допустимой антигенной нагрузки, стимулирующей продукцию гуморальных антител | |
Tognetti et al. | Evolution of Vaccines Formulation to Tackle the Challenge of Anti-Microbial Resistant Pathogens | |
Richert et al. | A TLR4 Agonist Induces Osteosarcoma Regression by Inducing an Antitumor Immune Response and Reprogramming M2 Macrophages to M1 Macrophages | |
Zhi et al. | Gamma-Irradiated Non-Capsule Group B Streptococcus Promotes T-Cell Dependent Immunity and Provides a Cross-Protective Reaction | |
Xianbo et al. | Fuzheng Jiedu Xiaoji Formula Remodelled Glycolytic Metabolism Manipulate Immune Responses in Hepatocellular Carcinoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1170421 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: JP NATIONAL INSTITUE OF INFECTIOUS DISEASE Free format text: FORMER OWNER: INDUSTRIAL COMPREHANSIVE TECHNOLOGLES INST. Effective date: 20150416 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150416 Address after: Tokyo, Japan Patentee after: Nat Inst Of Infectious Diseases Patentee after: M. Bio Technology Inc. Address before: Tokyo, Japan Patentee before: Independent Administrative Corporation Industrial Comprehansive Technologles Institute Patentee before: Nat Inst Of Infectious Diseases Patentee before: M. Bio Technology Inc. |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1170421 Country of ref document: HK |